International Journal of Molecular Sciences Review Emerging Roles of Matricellular Proteins in Systemic Sclerosis Daniel Feng 1,2 and Casimiro Gerarduzzi 1,2,3,* 1 Département de Pharmacologie et Physiologie, Faculté de Médecine, Université de Montréal, Montréal, QC H3T 1J4, Canada;
[email protected] 2 Centre de recherche de l’Hôpital Maisonneuve-Rosemont, Faculté de Médecine, Centre affilié à l’Université de Montréal, Montréal, QC H1T 2M4, Canada 3 Département de Médecine, Faculté de Médecine, Université de Montréal, Montréal, QC H3T 1J4, Canada * Correspondence:
[email protected]; Tel.: +1-514-252-3400 (ext. 2813) Received: 31 May 2020; Accepted: 13 June 2020; Published: 6 July 2020 Abstract: Systemic sclerosis is a rare chronic heterogenous disease that involves inflammation and vasculopathy, and converges in end-stage development of multisystem tissue fibrosis. The loss of tight spatial distribution and temporal expression of proteins in the extracellular matrix (ECM) leads to progressive organ stiffening, which is a hallmark of fibrotic disease. A group of nonstructural matrix proteins, known as matricellular proteins (MCPs) are implicated in dysregulated processes that drive fibrosis such as ECM remodeling and various cellular behaviors. Accordingly, MCPs have been described in the context of fibrosis in sclerosis (SSc) as predictive disease biomarkers and regulators of ECM synthesis, with promising therapeutic potential. In this present review, an informative summary of major MCPs is presented highlighting their clear correlations to SSc- fibrosis. Keywords: systemic sclerosis; fibrosis; extracellular matrix; matricellular proteins; myofibroblasts; biomarkers/therapeutics 1. Introduction Systemic sclerosis (SSc) is a rare idiopathic disease that presents as a trifecta of compounding chronic abnormalities driven by autoimmunity, vasculopathy, and systemic tissue fibrosis [1].